pieris.com - PIRS Company profit before taxes, interest and amortization
Pieris Pharmaceuticals (PIRS) protects its business through Anticalin patents, although capital restructuring has temporarily weakened its market position. Pieris Pharmaceuticals (PIRS) is implementing ESG standards in protein production to ensure ethical testing. Stephen Yarrow is currently reviewing the drug portfolio in search of new partners. Absolute operating profit reflects the cash flow dynamics, with the metric standing at 0.00, allowing for a real-time assessment of the issuer's current financial stability.
Summary analytical data breakdowns for Pieris Pharmaceuticals, Inc. (PIRS)
- market value and analyst target forecast:
- issuer market value details:
- issuer book value statistics:
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio Pieris Pharmaceuticals|PIRS - Long-Term Debt to Equity|Current Liabilities to Equity Pieris Pharmaceuticals Inc|PIRS - Company Aggregate Debts|Debts to Net Assets Pieris Pharmaceuticals|PIRS - Company Long-Term Debts|Short-Term Debt Pieris Pharmaceuticals|Intermediate Coverage Ratio pieris.com
- earnings and market ratios statistics:
PIRS - Net Profit|Company Profit Forecast Pieris Pharmaceuticals|PIRS - Price to Earnings Ratio|Market Cap to Projected Earnings pieris.com|PIRS - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Pieris Pharmaceuticals|PIRS - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months Pieris Pharmaceuticals|PIRS - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months pieris.com|PIRS - Earnings growth in current year|Earnings growth forecast for next year Pieris Pharmaceuticals
Summary company analytics:PIRS Pieris Pharma
Pieris Pharmaceuticals (PIRS) focuses on R&D, outsourcing the production of protein drugs to external contract manufacturing organizations to minimize capital expenditures. This specific operational model is reflected in the company's EBITDA, which captures the net cash flow from core operations before interest and depreciation, allowing investors to identify hidden cost increases behind one-time spikes in the curve and assess the real stability of the capital.
Who Pieris Pharmaceuticals competes with
Haleon Corp (HLN) - Profit before interest, taxes and amortization|KVUE: Operating profit before deduction of amortization|veronapharma.com - Company profit before taxes, interest and amortization|MENS: Operating profit EBITDA|Ligand Pharmaceuticals Incorporated - Income before deduction of interest, taxes and amortization|AMRX (Amneal Pharmaceuticals Inc) - Operating profit EBITDA|Profit before interest, taxes and amortization Perrigo Corp PRGO|Profit before payment of interest, taxes and amortization Alvotech (ALVO)|LQDA (liquidia.com) - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Galapagos GLPG|ANIP (ANI Pharmaceuticals Inc) - Profit before deduction of interest, taxes, depreciation and amortization|MannKind Corp. - Operating profit EBITDA|Operating income before deduction of amortization Amphastar Corp AMPH|PCRX: Operating profit EBITDA|Profit before interest, taxes and amortization ars-pharma.com (SPRY)|Profit before payment of interest, taxes and amortization Theravance Biopharma, Inc.|AQST: Income before deduction of interest, taxes and amortization|Operating profit EBITDA SCPH|Operating income before deduction of amortization tectonictx.com|Profit before payment of interest, taxes and amortization Tonix Pharmaceuticals TNXP|Operating income before deduction of amortization SXT Pharmaceuticals (SXTC)|EPRX: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization BHST (BioHarvest Sciences, Inc.)|Invizyne Technologies, Inc. (EXOZ) - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization ORMP (Oramed Pharmaceuticals Inc.)|ENTX (Entera Bio Ltd) - Operating profit EBITDA|HYFT: Income before deduction of interest, taxes and amortization|Operating profit EBITDA ABVC|Operating profit EBITDA Cumberland Pharmaceuticals Inc (CPIX)|Profit before payment of interest, taxes and amortization Quantum BioPharma Limited QNTM|Income before deduction of interest, taxes and amortization FGEN|TELO - Profit before payment of interest, taxes and amortization|Rani Therapeutics (RANI) - Operating profit before deduction of amortization|SNYR: Operating profit EBITDA|Rallybio (RLYB) - Operating profit EBITDA|LEXX (Lexaria Bioscience Corp) - Operating profit EBITDA|Operating profit before deduction of amortization Pulmatrix Corporation (PULM)|Operating profit EBITDA PTHL|APM - Profit before interest, taxes and amortization|Lyra Therapeutics - Operating profit before deduction of amortization|Operating profit EBITDA Impact BioMedical, Inc. IBO|TNFA: Operating profit before deduction of amortization|cbdMD, Inc. - Company profit before taxes, interest and amortization|PRFX: Operating profit EBITDA|CYTO - Operating income before deduction of amortization|LIPO (Lipella Pharmaceuticals, Inc.) - Operating profit EBITDA|Operating profit before deduction of amortization OptiNose Inc (OPTN)|Operating profit EBITDA PROC|Operating profit EBITDA Petros Pharma (PTPI)|Profit before payment of interest, taxes and amortization Qilian International QLI|acelyrin.com - Profit before payment of interest, taxes and amortization|TFFP - Profit before payment of interest, taxes and amortization
